Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Esophageal Neoplasms × anlotinib × Clear all

Status

Completed 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 21 Small Cell Lung Carcinoma 11 Sarcoma 7 Breast Neoplasms 7 Carcinoma, Hepatocellular 6 Lung Neoplasms 5 Triple Negative Breast Neoplasms 4 Stomach Neoplasms 4 Ovarian Neoplasms 4 NSCLC 3 Glioma 3 Esophageal Squamous Cell Carcinoma 3 Carcinoma 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Thyroid Neoplasms 2 Pheochromocytoma 2 Paraganglioma 2 Non-squamous Non-small Cell Lung Cancer 2 Neoplasms 2 Liver Neoplasms 2 Gynecological Cancer 2 Endometrial Neoplasms 2 Digestive System Neoplasms 2 Advanced Solid Tumor 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Cancer Limited Stage 1 Sarcoma, Ewing 1 SHR-1210 1 Recurrence 1

Interventions

Cisplatin 25 Paclitaxel 24 Radiotherapy 18 Fluorouracil 16 camrelizumab 10 Radiation 10 Oxaliplatin 9 Docetaxel 9 Carboplatin 9 Capecitabine 8 Surgical Procedures, Operative 7 Esophagectomy 7 Endoscopic Mucosal Resection 6 Drug Therapy 6 apatinib 5 Radiotherapy, Intensity-Modulated 5 Leucovorin 5 nedaplatin 4 Irinotecan 4 Endoscopy 4 Albumin-Bound Paclitaxel 4 pembrolizumab 3 TP protocol 3 Radiotherapy, Adjuvant 3 Preoperative Exercise 3 Neoadjuvant Therapy 3 Chemoradiotherapy 3 Cetuximab 3 olaparib 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04966611 2021-07-19

Anlotinib for Esophageal Cancer (AFEC)

Anyang Tumor Hospital

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡